Despite the great successes with CAR T cell therapy in leukemia that have been published previously by our group and others [3–7], up to 60% of relapses after CD19 CAR T cell therapy are characterized by CD19 antigen loss, which involves several different mechanisms [8–10]. Here, CD19 is linked to leukemia.